Thelansis

 Oral mucositis (OM) stands as the most prevalent and incapacitating complication of cancer chemotherapy and radiotherapy. It manifests through inflammation and ulceration within the oral cavity, induced by chemotherapeutic agents and radiotherapy in cancer treatment. Common symptoms encompass varying degrees of erythema, atrophy, ulceration, and mucosal swelling. This condition significantly deteriorates patients' quality of life (QOL). Potential complications include pain, heightened susceptibility to local and systemic infections, bleeding, decreased food intake, treatment delays, chemotherapy dose reductions, prolonged hospitalization, financial burdens, and, in severe cases, life-threatening diseases like septicemia in neutropenic scenarios. Currently, there is no approved medical treatment for OM. However, alpelisib, an FDA-approved PIK3CA inhibitor used in oncology, has shown promise in preclinical models and patient trials. Management primarily revolves around supportive ca

  Oral Mucositis (OM), also called stomatitis, is the most common, debilitating complication of cancer chemotherapy and radiotherapy, characterized by inflammation and ulceration in the oral cavity caused by the chemotherapeutic drug substances and radiotherapy used in cancer treatment. Typical manifestations of Oral Mucositis are varying degrees of erythema, atrophy, ulceration, and mucosa swelling. It has a significant negative impact on patients’ quality of life (QOL). Potential complications of OM include pain, increased the risk of local and systemic infections, bleeding, insufficient food intake, delays in the administration of radiotherapy and or chemotherapy, a dose reduction of the chemotherapy drugs, increased the length of hospital stays, associated economic burdens and in some cases life-threatening infections (septicemia in neutropenic instances). Mucositis is one of the most generally reported toxicities of mTOR inhibitors, and in some studies, it was the dose-limiting to

  Oral Mucositis (OM), also called stomatitis, is the most common, debilitating complication of cancer chemotherapy and radiotherapy, characterized by inflammation and ulceration in the oral cavity caused by the chemotherapeutic drug substances and radiotherapy used in cancer treatment. Typical manifestations of Oral Mucositis are varying degrees of erythema, atrophy, ulceration, and mucosa swelling. It has a significant negative impact on patients’ quality of life (QOL). Potential complications of OM include pain, increased the risk of local and systemic infections, bleeding, insufficient food intake, delays in the administration of radiotherapy and or chemotherapy, a dose reduction of the chemotherapy drugs, increased the length of hospital stays, associated economic burdens and in some cases life-threatening infections (septicemia in neutropenic instances). Mucositis is one of the most generally reported toxicities of mTOR inhibitors, and in some studies, it was the dose-limiting to